A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | MicrobiomeTrials
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-09-20Est. Completion: 2027-06-08
Enrollment target: 232 participants
Locations
City of Hope - Duarte Cancer Center, Duarte, California, United States
M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center, Minneapolis, Minnesota, United States
XCancer Omaha, Omaha, Nebraska, United States
The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston, Texas, United States
Utah Cancer Specialists Cancer Center - Medical Oncology, Salt Lake City, Utah, United States
Centre Hospitalier de l'Universite de Montreal (CHUM) | Oncology, Montreal, Quebec, Canada
Research Institute of the McGill University Health Centre | McConnell Centre for Innovative Medicine, Montreal, Quebec, Canada
Centre hospitalier universitaire de Sherbrooke (CHUS) | Oncology, Sherbrooke, Quebec, Canada
Kuopio University Hospital, Kuopion yliopistollinen sairaala (KYS) - Syövänhoitokeskus, Kuopio, Northern Savonia, Finland
Tampere University Hospital, Tampereen yliopistollinen sairaala (TAYS) - Syöpäkeskus, Tampere, Pirkanmaa, Finland
CRST Oy - Clinical Research Services Turku, Turku, Southwest Finland, Finland
HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus, Helsinki, Uusimaa, Finland
Docrates Mehiläinen Syöpäsairaala, Helsinki, Uusimaa, Finland
Istituto Europeo di Oncologia s.r.l - Medicina Nucleare, Milan, Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale - S. C. Medicina Nucleare e Terapia Metabolica, Naples, Italy
Erasmus Medisch Centrum, Rotterdam, South Holland, Netherlands
Universitair Medisch Centrum Groningen, Groningen, Netherlands
Skånes Universitetssjukhus - Lund - Onkologens kliniska forskningsenhet, Lund, Skåne County, Sweden
Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC, Stockholm, Stockholm County, Sweden
Akademiska sjukhuset i Uppsala - Fas 1-enheten, Uppsala, Uppsala County, Sweden
Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH, Gothenburg, Västra Götaland County, Sweden
Kantonsspital Baden, Baden, Canton of Aargau, Switzerland
Universitätsspital Basel, Basel, Canton of Basel-City, Switzerland
Cambridge University Hospitals NHS Foundation Trust | Addenbrookes Hospital - Clinical Research Centre, Cambridge, Cambridgeshire, United Kingdom
University College London Hospitals NHS Foundation Trust | University College Hospital - NIHR UCLH Clinical Research Facility, London, Greater London, United Kingdom
The Royal Marsden NHS Foundation Trust | Sutton - Oak Foundation Drug Development Unit, Sutton, Surrey, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust | Freeman Hospital - Cancer Trials Research Centre, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Other microbiome trials you might be interested in
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) rad…
Los Angeles, United StatesEst. completion Dec 31, 2026